CD274 and neoplasm: Although some studies have shown that the benefits seem to be superior for specific histotypes [52], or are only seen in ever-smokers [53,54], there is also evidence of an improved efficacy and tolerability of second-line immunotherapy with respect to standard chemotherapy in patients with different sites of metastasis, chemotherapy combinations (independent of tumor PD-L1 expression), and histology [54].